PTC Therapeutics CEO sells 10,292 shares in tax sale

PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported an automatic sale of 10,292 shares of common stock on 2026-08-04 at $68.57 per share.

Rhea-AI Filing Summary

PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported an automatic sale of 10,292 shares of common stock on 2026-08-04 at $68.57 per share. The sale was executed under an irrevocable sell-to-cover election pursuant to a Rule 10b5-1 trading plan to satisfy tax withholding obligations upon vesting of 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs. Following this transaction, Klein directly holds 383,868 shares of common stock, which include 162 shares acquired through the employee stock purchase plan for the period ended 2026-06-30.

Insider Trade Summary 10b5-1

Net Seller: 10,292 shares

Net Sell 1 txn

Insider Klein Matthew B.

Role CHIEF EXECUTIVE OFFICER

Sold 10,292 shs ($706K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	10,292	$68.57	$706K

Holdings After Transaction: Common Stock — 383,868 shares (Direct)

Footnotes (2)

1. F1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of the 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs.
2. F2. Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026.

Key Figures

Shares sold: 10,292 shares Sale price per share: $68.57 Shares held after transaction: 383,868 shares +3 more

6 metrics

Shares sold 10,292 shares Common stock sold on 2026-08-04 in an automatic sell-to-cover transaction

Sale price per share $68.57 Per-share price for 10,292 common shares sold on 2026-08-04

Shares held after transaction 383,868 shares Directly owned common shares by Matthew B. Klein following the reported sale

RSUs vested 25,000 RSUs Restricted stock units vesting that triggered the tax sell-to-cover transaction

RSU grant size 75,000 RSUs Total RSUs in the August 1, 2025 equity grant referenced in the footnote

ESPP shares included 162 shares Common shares acquired under the employee stock purchase plan for the period ended 2026-06-30

Key Terms

sell to cover, RSUs, employee stock purchase plan

3 terms

sell to cover financial

"shares automatically sold pursuant to an irrevocable sell to cover election"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

RSUs financial

"vesting of the 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

employee stock purchase plan financial

"shares of common stock acquired under the Issuer's employee stock purchase plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PTC Therapeutics (PTCT) disclose for CEO Matthew B. Klein?

PTC Therapeutics disclosed that CEO Matthew B. Klein sold 10,292 shares of common stock on 2026-08-04 at $68.57 per share. The sale was an automatic sell-to-cover transaction to satisfy tax withholding on vesting restricted stock units, not a discretionary open-market trade.

Why did the PTC Therapeutics (PTCT) CEO sell 10,292 shares?

The 10,292 shares were sold automatically under an irrevocable sell-to-cover election tied to a Rule 10b5-1 trading plan. The sale satisfied tax withholding obligations related to the vesting of 25,000 RSUs from a grant of 75,000 RSUs dated August 1, 2025.

How many PTC Therapeutics (PTCT) shares does the CEO hold after this Form 4 transaction?

After the reported transaction, CEO Matthew B. Klein directly holds 383,868 shares of PTC Therapeutics common stock. This figure includes 162 shares acquired through the company’s employee stock purchase plan for the period ended 2026-06-30.

Was the PTC Therapeutics (PTCT) CEO’s sale made under a Rule 10b5-1 trading plan?

Yes. The filing affirms the transaction under a Rule 10b5-1 trading plan, and the footnote describes an irrevocable sell-to-cover election. This indicates the timing and amount of shares sold for taxes were pre-arranged rather than discretionary.

What equity awards were involved in the PTC Therapeutics (PTCT) CEO’s tax-related share sale?

The tax-related sale related to the vesting of 25,000 restricted stock units (RSUs) from an August 1, 2025 grant totaling 75,000 RSUs. Shares sold under the automatic election helped cover the associated tax withholding obligations at vesting.

Did PTC Therapeutics (PTCT) note any employee stock purchase plan shares for the CEO?

Yes. The reported post-transaction holdings of 383,868 shares explicitly include 162 shares acquired by CEO Matthew B. Klein under the company’s employee stock purchase plan for the period ended 2026-06-30, as disclosed in a footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 05:20 PM Accepted by SEC EDGAR 08/06/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Matthew B.

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/04/2026		S(1)		10,292	D	$68.57	383,868(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of the 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs.

2. Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026.

	/s/ Avraham S. Adler, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)